The companies’ submission related only to the use of dapagliflozin when used in combination with insulin. The SMC has previously accepted dapagliflozin for restricted use in combination with metformin, when metformin alone with diet and exercise does not provide adequate glycaemic control and a sulphonylurea is inappropriate.